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ABSTRACT 26 
Objectives: The slow development of major advances in drug discovery for the treatment of 27 
Mycobacterium tuberculosis (Mtb) infection have led to a compelling need for evaluation of 28 
more effective drug therapies against tuberculosis. New classes of drugs are constantly 29 
being evaluated for anti-mycobacterial activity with currently a very limited number of new 30 
drugs approved for TB treatment. Minor Groove Binders (MGBs) have previously revealed 31 
promising anti-microbial activity against various infectious agents; however have not yet 32 
been screened against Mtb.  33 
Methods: Mycobactericidal activity of 96 MGB compounds against Mtb was determined 34 
using H37Rv-GFP microplate assay. MGB hits were screened for their intracellular 35 
mycobactericidal efficacy against clinical Beijing Mtb strain HN878 in bone marrow-derived 36 
macrophages using standard colony-forming unit counting. Cell viability was assessed by 37 
CellTiter-Blue assays. Selected MGB were encapsulated into non-ionic surfactant vesicles 38 
(NIVs) for drug delivery system evaluation. 39 
Results: H37Rv-GFP screening yielded a hitlist of 7 compounds at an MIC99 between 0.39 40 
and 1.56 μM. MGB-362 and MGB-364 displayed intracellular mycobactericidal activity 41 
against Mtb HN878 at MIC50 of 4.09 μM and 4.19 μM respectively, whilst being non-toxic. 42 
Subsequent encapsulation into NIVs demonstrated a 1.6 and 2.1-fold increased intracellular 43 
mycobacterial activity, similar to that of rifampicin when compared to MGB alone formulation.  44 
Conclusions: MGBs anti-mycobacterial activities together with non-toxic properties indicate 45 
that MGB compounds constitute an important new class of drug/chemical entity, which holds 46 
promise in future anti-TB therapy. Furthermore, NIVs ability to better deliver entrapped MGB 47 
compounds to an intracellular Mtb infection has provided merit for further preclinical 48 
evaluation. 49 
50 
Introduction 51 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), has become the 52 
top infectious killer worldwide. According to the 2016 World Health Organization (WHO) 53 
Global Tuberculosis Report,1 TB killed approximately 1.8 million people in 2015, up from 1.5 54 
million deaths in 2014.2 The current six-month treatment regimen for drug-susceptible Mtb, 55 
although still effective in most cases, is gradually becoming ineffective due to increasing 56 
resistance against the drugs used to treat TB.3 Several advances have been made in the 57 
field of TB drug discovery, spearheaded by global partnerships. For example, the Global 58 
Alliance for TB Drug Development currently manages the largest array of novel anti-TB drug 59 
compounds and novel regimens for MDR and XDR TB.4 Other initiatives to eradicate TB 60 
include the STOP TB partnership that includes an international working group to develop 61 
new TB drugs.5 Furthermore, several large consortia of pharmaceutical companies (TB Drug 62 
Accelerator) and academia (MM4TB) drive the discovery of new TB drugs.6 Despite the 63 
progress in the pipeline for new diagnostics, drugs, regimens, and vaccines, research 64 
remains relentlessly underfunded. As a consequence, only a few new drugs have been 65 
approved for clinical use, i.e. delamanid, bedaquiline and pretomanid, and only ten new 66 
drugs are in advanced phases of clinical trials as of 2016.7, 8 With the slow development of 67 
major advances in anti-mycobacterial drug discovery and the emergence of multi-drug-and 68 
extremely drug-resistant TB, there is an urgent need for the development of more effective 69 
therapies and formulations of existing drugs for the treatment of TB.8, 9 In the area of novel 70 
therapeutics discovery, progress has been made in developing new drug classes such as 71 
benzothiazinones, which inhibit cell wall arabinan synthesis, and imidazopyridines, which 72 
inhibit respiratory chain ATP synthesis.10, 11 Minor Groove Binder compounds (MGBs) have 73 
revealed promising antibacterial properties, but have not yet been investigated for their anti-74 
mycobacterial activity against Mtb in vitro. 75 
 Derived from the natural product distamycin, MGBs are a class of compounds that 76 
selectively bind to the minor groove of bacterial DNA with their helical structure matching 77 
that of DNA.12 Most often, proteins binding to bacterial DNA bind to the major groove, 78 
leaving the minor groove exposed and thus, a vacant target for MGBs. Natural forms of 79 
MGBs are currently used in clinical treatment of disease. For example, aromatic diamidines, 80 
such as pentamidine,13, 14 and berenil,15 known to bind to the minor groove at adenosine-81 
thymine tracts, have been administered clinically against human African trypanosomiasis 82 
and Pneumocystis carinii pneumonia.16-18 MGBs display a wide variety of activity profiles 83 
against many infectious organisms evaluated, including Gram-positive bacteria,19 84 
Mycobacterium aurum,20 chloroquine sensitive and resistant Plasmodium falciparum,21 and 85 
Trypanosoma brucei brucei.17 In partnership with MGB-Biopharma, one MGB compound has 86 
successfully completed phase I clinical trials for the treatment of Clostridium difficile 87 
infections.22 We recently screened a limited number of MGBs for their anti-mycobacterial 88 
activity against the laboratory Mtb H37Rv strain with MIC99 reaching 3.1 uM.23 We have now 89 
further extended this work by producing more active MGBs with higher MIC99 values against 90 
Mtb H37Rv. In addition we examined the anti-mycobacterial activity of MGBs against 91 
intracellular clinical HN878 Beijing strain of Mtb and evaluated the effect of MGBs exposure 92 
on cell viability in macrophages.  93 
 Oral drug administration has various limitations such as drug inefficiency resulting 94 
from drug insolubility caused by gastric low pH or poor absorbance in the gastrointestinal 95 
tract. However, an effective drug delivery system can improve drug retention at the site of 96 
infection. Therefore, an ability to deliver the drug to the site of infection may provide a 97 
sustained drug concentration enabling increased effectiveness of a drug against its target. In 98 
the case of pulmonary TB treatment, oral drug administration leads to high systemic 99 
concentrations of the drugs with associated side effects such as liver toxicity and 100 
cytotoxicity, amongst others.24 Ultimately, the drawbacks associated with the oral 101 
administration of antibiotics laid the foundation for the development of innovative drug 102 
delivery approaches. The use of liposomes as a drug delivery system has been previously 103 
reported to reduce microbial drug resistance through faster drug delivery and increasing the 104 
antimicrobial drug concentration thereby preventing microbial drug efflux pump activity.25 105 
Liposome encapsulated drugs kill microbes faster before microbial mutations can develop. 106 
For example the incorporation of the antibiotic levofloxacin into liposomes improved the anti-107 
mycobacterial activity to kill Mtb strain resistant to levofloxacin.26 Other drug delivery 108 
systems such as non-ionic surfactant vesicles (NIV) have the ability to encapsulate both 109 
hydrophobic and hydrophilic drugs for direct delivery to the site of infection.27 NIVs are small 110 
colloidal particles made of a non-aqueous, non-ionic surfactant bilayer that surrounds a 111 
central aqueous compartment. They are thermodynamically stable, easily manufactured and 112 
do not require special storage conditions. One of the major advantages of NIVs is that they 113 
are able to entrap different types of drug substances and can have their size altered. Their 114 
capacity to improve the delivery of small molecules is an important trait that allows for 115 
precise targeting of deposition of particles within the respiratory tract. Previous studies have 116 
shown NIVs to be a promising inhalable drug delivery system against pulmonary 117 
aspergillosis with aerosolized amphotericin B (AMB)-NIV administration reducing fungal lung 118 
burden when compared to AMB solution only.28 More recent studies are showing 119 
antibacterial action of moxiflacin29 and cefixime30 and antiviral action of nevirapine31 in NIV 120 
formulations. Although many different drug delivery systems have been utilised to entrap 121 
first-line TB drugs,32 only a few have systematically explored their anti-mycobacterial activity 122 
against Mtb and against intracellular Mtb in infected primary macrophages. Thus, we have 123 
investigated the use of NIVs as a drug delivery system on the improvement of delivery and 124 
efficacy of novel MGB compounds to Mtb-infected macrophages.  125 
Materials and methods 126 
Minor Groove Binder compounds 127 
MGB compounds were synthesized using distamycin template, a natural product with known 128 
infective properties as previously reported.17, 23, 33 Alterations of the head, tail, side chains 129 
and body resulted in a number of diverse compounds with later synthesis driven by acquired 130 
screening data (Table S1). MGBs were re-suspended in DMSO to a concentration of 1.25 131 
mM and were stored at -80˚C. 132 
 133 
Preparation of compounds and non-ionic surfactant vesicles 134 
MGB compounds (Stock: 1.25 mM) and rifampicin (Stock: 20 mM) were diluted to a starting 135 
concentration of 50 μM followed by 2-fold dilutions in 7H9 broth medium or DMEM to yield 136 
required screening range. Freeze dried NIVs were prepared as previously described28 and 137 
rehydrated in DMEM + 10% FCS (Gibco, Thermofisher Scientific, USA) to a NIV 138 
concentration range of 23-5000 μM (empty NIV) and subsequently added to bone marrow-139 
derived macrophages (BMDMs) in order to assess cell viability through CellTiter-Blue 140 
(Promega, Wisconsin, USA) assay with fluorescence detection at (544ex/590em nm). 141 
Subsequently, drug-NIV solutions were prepared in DMEM + 10% FCS at 2:5 molar ratio 142 
(MGB: NIV) at compound two-fold serial dilution range from 1.56 to 12.5 μM (3.91-31.25 μM 143 
NIV) to assess cell viability and intracellular anti-mycobacterial activity. Two-fold serial drug 144 
dilution was performed as previously reported in other drug screening studies.34  145 
 146 
H37Rv-GFP microplate screening assay 147 
MGB compounds were screened for their anti-mycobacterial activity using 96-well, black 148 
clear flat-bottom microplates (Greiner Bio-One, Germany) as previously reported.35, 36 Single 149 
cell suspension of H37Rv-GFP from frozen stock with working concentration of 1x106 150 
cfu/mL, was prepared in Middlebrook 7H9 supplemented with 25 mg/l kanamycin, 10% 151 
Middlebrook OADC (v/v) and 0.05% tween 80 (w/v). 100 μL of H37Rv-GFP at a 152 
concentration of 1x105 cfu/well was added to each experimental well. 100 μL of drug 153 
compounds prepared in 7H9 broth supplemented with 25 mg/L kanamycin to generate 154 
0.195-50 μM screening range, was added to well containing H37Rv-GFP for final screening 155 
range of 0.0977-25 μM. Wells containing compound only at the highest screening 156 
concentration were used to detect autofluorescence of compounds and broth (vehicle 157 
control). Fluorescence (485ex /520em nm) was measured at designated time points; days 0, 4, 158 
8, 10 and 12 with BMG Labtech Omega Plate Reader (Germany). The addition of sterile 159 
water to the outer wells of each plate served to minimize the evaporation. Time intervals 160 
were selected as previously reported in other drug screening studies.36 161 
 162 
Bone marrow-derived macrophages generation and Mtb infection  163 
BMDMs were generated from 8-12 week old C57BL/6 mice as previously reported.37  After 164 
differentiation, BMDMs were plated into 96-well plates (Nunc, Denmark) at 2 x 105 cells per 165 
well. Following overnight adherence, BMDMs were then infected with Mtb HN878 (MOI=5) 166 
and cultured at 37˚C under 5% CO2 for 4 hours. BMDMs were washed once with pre-167 
warmed culture media to remove extracellular bacteria or lysed and lysates plated on 7H10 168 
agar plates supplemented with 10% OADC and 0.5% glycerol for cfu counting to determine 169 
bacilli uptake. Drug compounds prepared in DMEM media supplemented with 10% FCS at 170 
defined concentrations were added to infected BMDMs to determine anti-mycobacterial 171 
activity and cell viability. After 5 days of culture, cells were lysed for cfu plating or assessed 172 
for cell viability by CellTiter-Blue assay. 173 
 174 
Statistical analysis 175 
All data were analysed using R, a student t-test (two-tailed with equal variance) or unless 176 
otherwise stated in figure legends. A *p value of less 0.05 was considered significant, with 177 
**p < 0.01 and ***p < 0.001.  178 
Results 179 
Minimum inhibitory concentration (MIC99) of MGB compounds against H37Rv-180 
GFP 181 
We screened 96 MGBs for their anti-mycobacterial activity against GFP-labelled H37Rv Mtb 182 
in liquid broth culture using a 96-well plate assay (Table 1). Relative fluorescence was 183 
measured at 0, 4, 8, 10 and 12 days in broth culture of MGBs (serially diluted from 25 µM to 184 
0.19 μM) to determine the minimum inhibitory concentration (MIC99) of MGBs required to 185 
eradicate 99% of Mtb (Figure 1). Hit compounds, defined as previously reported,38 were 186 
identified as drugs that were active at or below the threshold concentration of 3.12 μM. A 187 
hitlist of 7 compounds were identified with an MIC99 of 1.56 μM or less (Figure 1 and Table 188 
1). Rifampicin, which had an MIC of 0.0977 μM, was used as the positive control. The 189 
selected hit compounds were MGBs 362, 368, 361, 365, 359, 364 and 367 with MIC99 range 190 
(0.391-1.56 μM) and therefore were identified for subsequent intracellular anti-191 
mycobactericidal activity screening. 192 
 193 
Intracellular drug activity against clinical Mtb and macrophage cell viability  194 
The ability of anti-TB drug compounds to penetrate macrophages and induce 195 
mycobactericidal activity, while being non-toxic to the macrophages, is a salient property 196 
sought after in TB drug development. Hence, BMDMs were exposed to serial MGB drug 197 
concentrations from 1.56 to 12.5 μM to evaluate their anti-mycobacterial activity against the 198 
clinical Mtb strain HN878, after 5 days of infection. Compounds were screened for the 199 
concentration which eradicated 50% of bacilli (MIC50, Figure 2A). Two of the 7 hit 200 
compounds identified from screening studies against Mtb in Figure 1 had good intracellular 201 
mycobacterial killing efficacy against Mtb-infected macrophages, with MIC50 values of 4.09 202 
μM (MGB 362) and 4.19 μM (MGB 364). Rifampicin, selected as a positive control, had a 203 
MIC50 of 1.7 μM. CellTiter-Blue cell viability assay was performed to assess for macrophage 204 
cell viability in MGBs-treated BMDMs after 5 days of exposure (Figure 2B). MGB 362 and 205 
364 and rifampicin had no significant effect on macrophage viability at the respective 206 
intracellular drug activity MIC50 concentrations (Figure 2B). These data suggests that MGB 207 
362 and 364 have an efficient intracellular anti-mycobacterial activity against Mtb while being 208 
non-toxic to the host cells. 209 
 210 
MBGs-NIV encapsulation increased intracellular drug activity against clinical 211 
strain of Mtb 212 
We next investigated whether encapsulating our hit MGB compounds into NIVs, a drug 213 
delivery system that was previously reported to improve drug delivery of amphotericin B to 214 
macrophages,28 would improve MGBs drug efficacy against the intracellular clinical HN878 215 
Mtb strain. We demonstrated that encapsulating MGBs into NIVs improved the intracellular 216 
anti-mycobacterial abilities by 2.1-fold for MGB 362, and 1.6-fold for MGB 364 in Mtb 217 
HN878-infected BMDMs, displaying a significant cfu reduction (P < 0.01) compared to 218 
controls (Figure 3A). The anti-mycobacterial killing activity of MGB 362-NIV and MGB 364-219 
NIV were similar to that of rifampicin. MGB-NIV 364 displayed a significant decreased cfu 220 
counts (P < 0.033) when compared to MGB alone. Furthermore, Mtb-infected macrophages 221 
were viable following MGB-NIV treatment (Figure 3B). Treatment with NIV-alone also had no 222 
significant effect on macrophage viability (data not shown). These results demonstrate that 223 
NIVs can act as a suitable delivery system by transporting MGB inside macrophages, the 224 
target cells for Mtb.  225 
Discussion 226 
MGB compounds have shown great potential for their use as antibacterial therapeutic 227 
agents.33 However, their activity against Mtb remains unknown. Here, we demonstrated the 228 
anti-mycobacterial (MIC99) properties of MGBs against Mtb (H37Rv-GFP) with a reliable 229 
screening method that enables the detection of most active compounds,39 using rifampicin 230 
as a positive control. All of the active MGB compounds belong to the well-established 231 
alkene-linked minor groove binder family discovered at the University of Strathclyde with 232 
high killing activities against different pathogens as previously reported.17, 19-21, 23, 33 Since the 233 
primary binding sites of all of these MGBs in the DNA minor groove are AT rich regions it is 234 
unlikely that target sequence specificity is responsible for the selectivity observed. This is 235 
true also for the active compounds against Mtb described here. However, it is more likely 236 
that activity and selectivity against a particular pathogen is caused by differential access to 237 
cells caused by differing cell wall and cell membrane structures in a way that with the current 238 
state of knowledge is idiosyncratic and unpredictable.33 What can be reliably stated is that 239 
the alkene-linked compounds are significantly the most biologically active of the Strathclyde 240 
MGB family. In general, MGBs with the most significant antibacterial activity possess a range 241 
of different tail groups, all of which are exemplified within the set in our screen. However, all 242 
of the most active MGBs identified in this study possess an amidine-containing tail group, 243 
which perhaps suggests an important role of tail group pKa for targeting mycobacteria. 244 
Screening of MGB compounds in the context of their cell viability and anti-245 
mycobacterial activity against intracellular clinical Mtb strain HN878 have identified two 246 
compounds with promising results, giving a hit rate of 2.1% (2/96). In most studies the hit 247 
rate for hit compounds is in the order of 1%, in-line with previous studies.40 These findings 248 
however warrant in vivo testing which aims to allow for better clinical therapeutic translation 249 
of the findings. The use of non-ionic surfactant vesicles (NIVs) has been demonstrated 250 
repeatedly in literature before and constitutes a prominent focus within current Mtb research 251 
in order to combat the infection.27, 41 NIVs given by nebulisation delivered amphotericin B to 252 
the lungs and liver with significantly improved treatment outcome when compared to AMB 253 
solution against pulmonary aspergillosis and visceral leishmaniasis.28 Our investigation of 254 
NIVs as a delivery device indeed demonstrate that NIVs can be used to enhance the efficacy 255 
of MGB compounds against HN878 in infected BMDMs whilst not increasing the toxicity of 256 
the drug to BMDMs. MGB contain hydrophobic head groups12 which allows for encapsulation 257 
into NIV. Liposomes have previously been reported to encapsulate an alkyl derivative of 258 
distamycin A42 which are naturally occurring backbones for MGB compound synthesis.  259 
NIVs ability to trap the drug within its hydrophilic/-phobic compartment allows the 260 
drug to be taken up by phagocytosis by the infected macrophage, thereby transporting the 261 
drug to the site of infection. Using NIV drug formulations resulted in higher drug levels 262 
compared to similar treatment with drug solution at the site of infection after treatment by the 263 
pulmonary or intravenous routes for water soluble43, 44 and lipid soluble drugs28. Studies in 264 
dogs treated by the intravenous route with a sodium stibogluconate-dextran (SSG)-NIV 265 
formulation increased the elimination half-life and the volume of distribution at steady state 266 
compared to SSG-dextran solution.45 Therefore NIV-MGB formulation can be a feasible 267 
pulmonary treatment for Mtb.  268 
 In conclusion, this study showed that MGBs constitute an important new class of 269 
drug/chemical entity with favourable anti-mycobacterial activity and holds promise in future 270 
anti-TB therapy. Furthermore, we demonstrate that NIVs contribute to better delivery of 271 
drugs to an intracellular infection and secondly act as a delivery device for entrapped MGB 272 
compounds and lastly serve as the initial step into future research of targeted delivery of 273 
entrapped drug to Mtb-infected cells.  274 
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  395 
Table 1. MIC99 of all screened MGBs against H37Rv-GFP. 7 hits were identified out of 96 396 
MGBs screened. MGBs marked with asterisk symbols were previously screened as 397 
reported.23     398 
 399 
Compound MIC99 Compound MIC99 Compound MIC99 
Rifampicin 0.0977 371 25 235 >25 
362 0.391 372 25 245 >25 
368 0.391 373 25 246 >25 
361 0.781 374 25 247 >25 
365 0.781 381 25 248 >25 
359 1.56 1 >25 270 >25 
364 1.56 2 >25 271 >25 
367 1.56 9 >25 283 >25 
353* 3.12 12 >25 286 >25 
354* 3.12 74* >25 287 >25 
391 3.12 85 >25 288 >25 
263 6.25 92 >25 289 >25 
343 6.25 114 >25 300 >25 
385 6.25 121 >25 303 >25 
386 6.25 122 >25 304 >25 
351* 12.5 123 >25 305 >25 
352* 12.5 124 >25 306 >25 
376 12.5 131 >25 322 >25 
377 12.5 134 >25 323 >25 
378 12.5 147 >25 324* >25 
379 12.5 154 >25 325 >25 
380 12.5 176 >25 329* >25 
383 12.5 185 >25 331* >25 
387 12.5 187 >25 332* >25 
390 12.5 188 >25 333* >25 
282 12.5 - 25 192 >25 334* >25 
4* 25 210 >25 335* >25 
116 25 212 >25 336* >25 
164 25 213 >25 338* >25 
292 25 214 >25 356 >25 
317* 25 222 >25 357 >25 
330* 25 234 >25 358 >25 
337 25     
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Figure 1. Screening of anti-mycobacterial activity of MGB compounds against H37Rv-GFP. 449 
Direct antimicrobial activity of MGB compounds at the drug concentration range of 0.195 - 25 450 
μM was tested against H37Rv-GFP (1x105 cfu/well) in 7H9 liquid broth culture using 451 
microplate assay. The anti-mycobacterial activity of MGB treatment on H37Rv-GFP was 452 
determined at a concentration-dependent manner by measuring fluorescence (485ex/520em 453 
nm) on days 0, 4, 8, 10 and 12. Data was corrected for background 7H9 fluorescence. Data 454 
show mean ± SEM of duplicates. 455 
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Figure 2. MIC50 of MGB compounds in HN878 Mtb-infected BMDMs and cell viability. A) The 497 
intracellular anti-mycobacterial activities of MGBs (1.5625-12.5 μM) and rifampicin (0.3906-498 
3.125 μM) were assessed by counting cfu at the respective concentration at 5 days post Mtb 499 
HN878 infection. MIC50 values of each drug compound were identified in GraphPad Prism by 500 
non-linear regression analysis. B) Macrophage cell viability was determined at 5 days of 501 
MGB compound exposure and measured by CellTiter-Blue assay with fluorescence 502 
detection at (544ex/590em nm). Data were corrected for background culture medium 503 
fluorescence and are shown mean ± SEM, representative of triplicates. Two-tailed Student’s 504 
t-test, *p < 0.05, **p < 0.01, *** p < 0.001 compared to control.  505 
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Figure 3. MGBs-NIV formulation intracellular mycobacterial activity in HN878 Mtb-infected 521 
BMDMs and cell viability. A) The intracellular anti-mycobacterial activity of MGBs only, 522 
MGBs-NIV formulation and rifampicin was determined in comparison to control (no drug 523 
treatment). Cfu was determined at 5 days post Mtb HN878 infection. B) Macrophage cell 524 
viability was determined at 5 days post Mtb HN878 infection and measured by CellTiter-Blue 525 
assay with fluorescence detection at (544ex/590em nm). Data were corrected for background 526 
culture media fluorescence and are shown as show mean ± SD, representative of triplicates. 527 
Two-tailed Student’s t-test, *p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. 528 
